Camp4 Therapeutics (Nasdaq:CAMP) - Stock Price, News & Analysis

CAMP Stock Overview

A clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. More details

CAMP fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Revenue is forecast to grow 71.04% per year

Analysts in good agreement that stock price will rise by 308%

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($0)

Earnings are forecast to decline by an average of 8.7% per year for the next 3 years

+ 2 more risks

Camp4 Therapeutics Corporation Competitors

Lineage Cell Therapeutics

NYSEAM:LCTX

US$126.5m

Cyteir Therapeutics

OTCPK:CYTT

US$108.3m

Adverum Biotechnologies

NasdaqCM:ADVM

US$127.9m

Inovio Pharmaceuticals

NasdaqCM:INO

US$107.8m

Price History & Performance

Summary of all time highs, changes and price drops for Camp4 Therapeutics
Historical stock prices
Current Share Price	US$4.94
52 Week High	US$12.30
52 Week Low	US$4.06
Beta	0
11 Month Change	-55.85%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-53.92%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	CAMP	US Biotechs	US Market
7D	-25.3%	4.0%	2.0%
1Y	n/a	18.0%	32.4%

Return vs Industry: Insufficient data to determine how CAMP performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how CAMP performed against the US Market.

Price Volatility

Is CAMP's price volatile compared to industry and market?
CAMP volatility
CAMP Average Weekly Movement	20.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Stable Share Price: CAMP's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine CAMP's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2015	58	Josh Mandel-Brehm	www.camp4tx.com

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001 for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP to treat synaptic Ras GTPase activating protein 1-related disorders.

Camp4 Therapeutics Corporation Fundamentals Summary

How do Camp4 Therapeutics's earnings and revenue compare to its market cap?
CAMP fundamental statistics
Market cap	US$86.99m
Earnings (TTM)	-US$51.50m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.9x

P/E Ratio

Is CAMP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CAMP income statement (TTM)
Revenue	US$0
Cost of Revenue	US$37.93m
Gross Profit	-US$37.93m
Other Expenses	US$13.58m
Earnings	-US$51.50m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.64
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	6.0%

How did CAMP perform over the long term?

See historical performance and comparison